Information Provided By: 
Fly News Breaks for April 18, 2018
RARE
Apr 18, 2018 | 06:21 EDT
JPMorgan analyst Cory Kasimov raised his price target for Ultragenyx to $72 from $66 after the FDA approved Crysvita pediatric and adult X-linked hypophosphatemia. The company expects net pricing of $160,000 and $200,000 in pediatric and adults, largely consistent with other rare disease pricing models, Kasimov tells investors in a research note. The analyst remains impressed by Ultragenyx's execution as it transitions to a commercial-stage company. He sees opportunity for the shares to appreciate in 2018 and keeps an Overweight rating on the name.
News For RARE From the Last 2 Days
